AIPPI 2016: Pay-for-delay deals come in for scrutiny

20-09-2016

AIPPI 2016: Pay-for-delay deals come in for scrutiny

Roman Sinichkin / Shutterstock.com

Pharmaceutical pay-for-delay deals worth less than around $10 million are unlikely to be challenged by the authorities in US courts, according to a speaker at the 2016 AIPPI World Congress in Milan.


AIPPI; AIPPI 2016; pay-for-delay deals; patent; generic drugs; pharmaceuticals

LSIPR